2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
22
Neoplasms
6
Carcinoma, Hepatocellular
5
Stomach Neoplasms
4
Recurrence
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Cancer
4
Uveal Melanoma
3
Urinary Bladder Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Liver Neoplasms
3
Colonic Neoplasms
3
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Glioma
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Basal Cell
2
Brain Neoplasms
2
Interventions
Cyclophosphamide
65
Peripheral Blood Stem Cell Transplantation
37
fludarabine phosphate
36
Doxorubicin
31
Etoposide
30
Vincristine
29
Whole-Body Irradiation
28
Rituximab
26
Prednisone
26
Brentuximab Vedotin
26
Mycophenolic Acid
25
Filgrastim
22
Cyclosporine
22
Methotrexate
20
Busulfan
19
Cytarabine
18
Radiotherapy
17
Antilymphocyte Serum
16
Tacrolimus
15
Melphalan
15
Carboplatin
14
Ifosfamide
13
Bortezomib
13
Methylprednisolone
12
Gemcitabine
11
Flow Cytometry
10
Lenalidomide
9
Dexamethasone
9
romidepsin
8
Vorinostat
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Large-Cell, Anaplastic
×
relatlimab
×
Clear all
NCT05255601
2026-02-25
RELATIVITY-069
Bristol-Myers Squibb
Phase 1/2
Completed
5 enrolled